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Abstract
Background: Recent studies have shown that triglyceride (TG), low-density lipoprotein cholesterol (LDL), and
high-density lipoprotein cholesterol (HDL) are related to the prevalence of cardiovascular autonomic neuropathy (CAN).
However, little is known about the association of lipid profile with diabetic cardiovascular autonomic neuropathy
(DCAN), or its severity in the Chinese population. The purpose of this study is to explore the extent of this
phenomenon using a Chinese sample.
Methods: A subgroup analysis on 455 diabetic patients with undiagnosed DCAN was performed to evaluate the
relationships of lipids profile and DCAN. DCAN was diagnosed if there were at least two abnormal cardiovascular
autonomic reflex test results, based on short-term heart rate variability tests. Multivariable logistic regression (MLR)was
carried out to control potential confounders for determining the independent association of variables with DCAN in
different models.
Results: MLR analysis indicated that TG was significantly and independently associated with DCAN when controlling
for confounding factors (P < 0.1 for two models). Additionally, TG combined with TC (LRS-1) and LDL (LRS-2) was
associated with this outcome (P < 0.1 for LRS-1 and LRS-2).
Conclusion: Our findings indicate that TG and the severity of lipids profile is significantly and independently associated
with DCAN, respectively.
Trial registration: ClinicalTrials.gov Identifier: NCT02461472, retrospectively registered 2 Jun, 2015
Keywords: Diabetic cardiac autonomic neuropathy, Association, Lipid profile, Chinese sample
Background
Dyslipidemia has become one of the most prevalent
non-communicable diseases worldwide, as reported by
the Global Burden of Disease (GBD) studies [1, 2]. Its
symptoms include elevated levels of total cholesterol
(TC), low-density lipoprotein cholesterol (LDL), triglyc-
erides (TG), or decreased high-density lipoprotein chol-
esterol (HDL). Following lifestyle changes in China
during the past 30 years, the rate of dyslipidemia in
China was 18.6 % in 2004, or about 160 million people.
Despite the huge number affected, only 3.5 % of men
and 3.4 % and women were treated, with 1.9 % and
1.5 % being controlled, respectively [3]. Recent data has
shown that only 55.9 % of outpatients in the top-ranked
hospitals in the major cities of China were treated for
dyslipidemia, with only 39.4 % of them achieving the
LDL goal [4].
Dyslipidemia is considered an important modifiable
risk factor for cardiometabolic (CM) diseases, and causes
morbidity and mortality worldwide [5]. Data published
recently indicates that CM risk factors are highly preva-
lent among youths and young adults, which poses a high
risk of death from diabetes and cardiovascular disease in
China [6]. The Chinese healthcare system is heavily bur-
dened by CM diseases, which are now the leading causes
of morbidity and mortality in China [7, 8]. Dyslipidemia
was highly common in type 2 diabetes (T2DM) patients,
and was up to 67.1 % in 2015 [4]. Dyslipidemia in
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T2DM is characterized by increased TG and LDL
decreased HDL, and increased free fatty acid. Patients
with both diabetes and dyslipidemia usually have a
higher risk of cardiovascular diseases, and experience
more severe clinical outcomes when compared to nondi-
abetic patients [9, 10].
Recent data has demonstrated that the TG/HDL ratio
and a smaller mean LDL particle size were related to the
prevalence of cardiac autonomic neuropathy in women
with T2DM in Korea [11]. However, little is known
about the association of lipid profile with DCAN, or its
severity in the Chinese population. Previously, we per-
formed a study on a Chinese sample to analyze this, and
to explore the relationship between blood pressure pro-
files and DCAN, which revealed that systolic blood pres-
sure and severity of blood pressure profiles was
significantly and independently associated with DCAN
[12]. In this study, we focused on exploring the extent to
which association of lipid profiles and its severity with
DCAN in a Chinese sample.
Methods
Study population
As mentioned earlier [13], we carried out a risk factors
survey for CAN on a random sample of the Chinese
population. Participants were recruited from rural and
urban communities in Shanghai. As described earlier
[12], a subgroup analysis was performed on diabetic par-
ticipants with undiagnosed CAN aged 30–80 years. We
analyzed subjects in screening visits between 2011 and
2013. Some subjects were excluded from the study to
eliminate potential confounding factors that may have
influenced their CA function. Briefly, the exclusion cri-
teria were as follows: history or findings of arrhythmia
and hyperthyroidism or hypothyroidism; pregnancy or
lactation; and/or serious hepatic or renal dysfunctions
(GFR < 30 mL/min/1.73 m2). A total of 455 diabetic par-
ticipants with complete clinical baseline data were avail-
able for the DCAN risk factor analysis. Written consent
was obtained from all patients before the study.
Ethics statement
This study was reviewed and received ethical approval
from the Ethics Committee at the Shanghai Tongji
Hospital. Permission to conduct the study was granted
by the Shanghai Tongji Hospital. The methods were
carried out in accordance with the approved guidelines.
Written informed consent was obtained from all study
participants.
Measurement
As mentioned earlier [12], the participants were inter-
viewed for the documentation of medical histories,
medication, and history of smoking habits. Laboratory
assessments of cardiovascular disease risk factors were
completed, along with standardized examination for
heart rate variability (HRV). All subjects underwent a
complete clinical baseline characteristics evaluation after
an eight-hour fasting, which included history and phys-
ical examination, heart rate and blood pressure, fasting
serum glucose and insulin, and fasting plasma lipids.
The assessments of demographical information, lipids
profiles, glucose profiles, renal function, indices of HRV,
and medical history were detailed earlier [12]. The day-
to-day and inter-assay coefficients of variation at the
central laboratory in our hospital, for all analyses, were
between 1 % and 3 %. Definitions of HTN, body mass
index (BMI), DM, and MetS were detailed in our earlier
studies [12, 13].
The study outcome
As mentioned in our earlier studies, we used short-term
HRV to evaluate CA function. HRV was measured non-
invasively by power spectral analysis. Before the CA
function assessment, participants were asked to avoid al-
cohol, smoking, and coffee for 24 h to help bring about
a calm and quiet condition. Subjects were studied while
awake in the supine position after 20 min of rest. Test-
ing times were between 8:00 and 11:00 in the morning.
A type-I FDP-1 HRV non-invasive detecting system was
used with software version 2.0 (Department of Biomedical
Engineering of Fudan University, Shanghai, China). In this
study, CAN was diagnosed from the results of at least two
abnormal cardiovascular autonomic reflex test results that
were based on short-term HRV tests [14–16].
Statistical analysis
Continuous variables were detected following normal
distribution, using the Kolmogorov-Smirnov Test. Var-
iables that were not normally distributed were log-
transformed to approximate normal distribution for
analysis. Results are described as mean ± SD or median,
unless stated otherwise. Differences in variables between
male and female participants were determined by un-
paired t-test. Between groups, differences in properties
were assessed by χ2 analysis.
We performed difference analyses on the prevalence of
DCAN among lipid profile indices with category vari-
ables. According to clinical reference values, TC was cat-
egorized by trinary variables (code 0: <5.18 mmol/L,
code 1: 5.18–6.19 mmol/L, and code 2: > 6.19 mmol/
L),TG was categorized by trinary variables (code 0:
<1.71 mmol/L, code 1: 1.71–2.25 mmol/L, and code 2: >
2.25 mmol/L), LDL was categorized by trinary variable-
s(code 0: <3.37 mmol/L, code 1: 3.37–4.14 mmol/L, and
code 2: > 4.14 mmol/L), and HDL was categorized by
binary variables (code 0: ≥1.04 mmol/L and code 1:
<1.04 mmol/L). Next, groups with similar prevalence of
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DCAN were combined into one group so as to gain lipid
profile indices categorized by binary variables.
Univariate logistic regression, to include lipid profiles
with continuous variables, was performed to determine
variables associated with DCAN and to estimate con-
founding factors that could possibly disturb the relation
between lipid profiles and DCAN.A lipid profile risk score
(LRS) was calculated for associations between severity of
lipid profile and DCAN. In this study, LRS-1 was the sum
of TC and TG with binary variables. Similarly, LRS-2,
LRS-3, and LRS-4 were derived from TG and LDL, TG
and HDL, and HDL and LDL, respectively. Multivariable
logistic regression (MLR) was carried out to control po-
tential confounders for determining the independent asso-
ciation of variables with DCAN in six models. The results
were analyzed using the Statistical Package for Social Sci-
ences for Windows, version 16.0 (SPSS, Chicago, IL,
USA). Tests were two-sided, and a p-value of < 0.05 was
considered significant. For multiple variable analysis, a p-
value of <0.10 was also considered significant.
Table 1 The clinical baseline characteristics of individuals
Variable Female Male Total sample P value
Demographic information
N 247 208 455 -
Age year 62.17 ± 8.37 63.54 ± 8.84 62.8 ± 8.61 0.016
Height cm 157.2 ± 5.99 167.95 ± 6.33 162.12 ± 8.15 <0.001
Weight kg 62.9 ± 11.3 71.05 ± 10.45 66.63 ± 11.65 <0.001
SBP mmHg 134.95 ± 21.33 133.55 ± 19.02 134.3 ± 20.3 0.305
DBP mmHg 81.2 ± 10.1 80.93 ± 10.16 81.08 ± 10.12 0.690
Lipid profile
TCmmol/L 5.64 ± 1.08 5.06 ± 1.07 5.38 ± 1.11 <0.001
TG mmol/L 1.99 ± 1.03 1.99 ± 1.34 1.99 ± 1.18 0.961
HDL mmol/L 1.38 ± 0.29 1.19 ± 0.28 1.3 ± 0.31 <0.001
LDL mmol/L 3.4 ± 0.86 3.14 ± 0.82 3.28 ± 0.85 <0.001
Glucose profile
FPG mmol/L 7.11 ± 2.56 7.61 ± 2.82 7.34 ± 2.69 0.006
PBG mmol/L 11.9 ± 4.25 12.07 ± 4.62 11.98 ± 4.42 0.583
FINSuIml 11.09 ± 24.53 9.68 ± 24.23 10.45 ± 24.39 0.388
Renal function
SCr μmolL 73.35 ± 23.1 90.93 ± 21.54 81.37 ± 24.04 <0.001
UA μmolL 280.17 ± 77.45 319.48 ± 89.66 298.09 ± 85.47 <0.001
HRV indices
HR bpm 74.96 ± 9.63 75.29 ± 11.27 75.11 ± 10.41 0.634
TP ms2 763.34 ± 635.42 728.25 ± 734.89 747.3 ± 682.53 0.440
LF ms2 152.57 ± 145.95 183.19 ± 293.24 166.57 ± 225.93 0.042
HF ms2 163.58 ± 193.2 138.57 ± 182.1 152.15 ± 188.51 0.046
LF/HF 1.66 ± 1.91 2.05 ± 2.33 1.84 ± 2.12 0.006
Medical history
Smokingyes,% 4(1.62 %) 85(40.87 %) 89(19.56 %) <0.001
DMD year 4.86 ± 6.29 5.73 ± 6.62 5.24 ± 6.45 0.063
HTNyes,% 318(64.37 %) 264(63.46 %) 582(63.96 %) 0.776
HTND year 5.62 ± 9.05 7.41 ± 10.96 6.42 ± 9.99 0.008
MetSyes,% 187(75.71 %) 143(68.75 %) 330(72.53 %) 0.019
DCANyes,% 67(27.13 %) 65(31.25 %) 132(29.01 %) 0.172
Note: SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, PBG plasma blood glucose, FINS fasting blood insulin, TC serum total
cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, SCr serum creatinine, HR heart rate, TP total power of
variance, LF low frequency, HF high frequency, MetS metabolic syndrome, DMD diabetes duration, HTN Hypertension, HTND Hypertension duration, DCAN diabetic
cardiovascular autonomic neuropathy
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Results
Clinical characteristics of participants
The baseline clinical characteristics of the 455 diabetic
participants were detailed earlier [12], and are also listed
in Table 1. There were 208 males and 247 females (mean
age62.17 ± 8.37 years) in the complete sample. There
were significant differences in TC, LDL, and HDL levels
between males and females (P value <0.05), but none in
TG between the two groups (P value =0.961). The level
of FPG was higher in males compared to females (P
value =0.006). Significant differences in the parameters
of renal function between males and females were re-
ported (P value <0.001). The mean duration of DM and
HTN was 5.24 and 6.42 years in the entire sample. The
prevalence of HTN, MetS, and DCAN was 63.96 %,
72.53 %, and 29.01 % in the whole sample, respectively.
Difference analysis in DCAN prevalence among lipid profile
There were no significant differences in DCAN preva-
lence among the three TC groups (27.01 % vs. 28.87 %
vs. 33.33 %, P = 0.452, Fig. 1a). Similarly, no significant
differences between the two groups were reported
(27.76 % vs. 33.33 %, P = 0.122, Fig. 1b). The DCAN
prevalence was 25.34 %, 29.13 %, and 35.25 % in the
three TG groups, respectively. However, a significant dif-
ference between the two groups was reported (P =0.022
and P for trend = 0.006, Fig. 2a). Additionally, the DCAN
prevalence was significantly higher in diabetic partici-
pants with a high TG level, as compared to those with a
low TG level (26.54 % vs. 35.25 %, P = 0.010, Fig. 2b). In
the LDL groups, no significant differences among the
three groups were reported (28.40 % vs. 28.13 % vs.
32.86 %, P =0.622, Fig. 3a). There were also no signifi-
cant differences between the two groups (28.31 % vs.
32.86 %, P = 0.276, Fig. 3b). Similarly, there were no sig-
nificant differences between the high HDL and low HDL
groups (28.89 % vs. 29.47 %, P = 0.371, Fig. 4).
Association analysis between lipid profile and DCAN
To estimate the association of various clinical factors
and DCAN univariate logistic regression models were
developed to include lipids profiles, age, gender, BMI,
glucose profiles, renal functions, and medical history. As
described earlier [12], the univariate logistic analyses in-
dicated that TG, age, BMI, glucose profiles, HTND,
DMD, and MetS were significantly associated with
DCAN (P < 0.05 for all, Table 2); however, there were no
significant associations of TC, LDL, and HDL with
DCAN (P >0.05 for all).
Multiple variables logistic regression to include lipids
profile, and controlling for potential confounding factors
of age, gender, smoking, BMI, blood pressure, glucose
profile, renal function, medical history, indicated that
there was a significant association between TG and
DCAN (P value =0.036OR = 1.25, 95 % CI: 1.015–1.54
for model 1, and P value = 0.096OR = 1.427, 95 % CI:
0.939–2.167 for model 2, Table 3). However, there was
no significant association of TC, LDL, or HDL with
DCAN (P < 0.05 for all).
Association analysis between severity of LRS and DCAN
There were significant differences among the three LRS-1
groups (25.48 % vs. 32.70 % vs. 37.84 %, P for difference =
0.018 and P for a trend =0.005, Fig. 5a). Similarly, signifi-
cant differences were seen among the three LRS-2 groups
(26.18 % vs. 32.08 % vs. 42.86 %, P for difference = 0.024
and P for a trend =0.007, Fig. 5b). In contrast, there were
no significant differences among the three groups
(27.14 % vs. 30.14 % vs. 37.50 %, P for difference = 0.140
and P for a trend =0.059, Fig. 5c). Additionally, no signifi-
cant differences were identified among the three groups
Fig. 1 Comparison of prevalence of diabetic cardiovascular autonomic
neuropathy (DCAN) according to serum total cholesterol (TC). a:
Comparison of DCAN prevalence according to TC with trinary
variables. DCAN prevalence was 27.01 %, 28.87 % and 33.33 % in the
three groups, respectively. No significant differences among the three
groups were reported (P = 0.452). b: Comparison of DCAN prevalence
according to TC with binary variables. DCAN prevalence was 27.76 %
and 33.33 % in the two groups, respectively. No significant differences
between the two groups were reported (P = 0.122)
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(28.14 % vs. 30.32 % vs. 40.00 %, P for difference =0.548
and P for a trend =0.363, Fig. 5d).
Multiple variables analysis indicated that there was a
significant association of severity of LRS-1 or LRS-2
with DCAN (P value =0.058 OR =1.337, 95 % CI: 0.990–
1.806 for LRS-1, and P value = 0.079 OR = 1.321, 95 %
CI:0.968–1.801 for LRS-2, Table 4). However, there was
no significant association of severity of LRS-3 or LRS4
with DCAN (P < 0.05 for all).
Discussion
A community-based, cross-sectional study was per-
formed to evaluate the relationship between lipids pro-
file and DCAN in the Chinese population. The
prevalence of HTN, MetS, and DCAN in the general
populace was similar to that seen in previous studies. As
our sample was a good representation of the entire
country, our findings might be applied effectively outside
the studied areas in China. In this study, we used LRS to
combine the information concerning lipids profile to es-
timate its severity. To the best of our knowledge, this is
the first use of LPS to model lipids profile and its sever-
ity, in order to explore the extent to which lipids profile
is associated with DCAN in the Chinese population.
Additionally, short-term HRV was measured non-
invasively by a power spectral analysis to evaluate the
CA function, due to this test having good reproducibility
and greater practicality for application.
Interestingly, our findings signified that TG was sig-
nificantly and independently associated with DCAN
when controlling for confounding factors including age,
BMI, glucose profiles, and medical history; however, no
association was found between TC, LDH and HDL, and
DCAN. In the different indices of lipid profiles, higher
levels of the sum of TG and TC, and TG and LDL, were
Fig. 2 Comparison of prevalence of diabetic cardiovascular
autonomic neuropathy (DCAN) according to triglyceride (TG). a:
Comparison of DCAN prevalence according to TG with trinary
variables. DCAN prevalence was 25.34 %, 29.13 % and 35.25 % in the
three groups, respectively. A significant differences among the three
groups were reported (P =0.022 and P for trend = 0.006). b:
Comparison of DCAN prevalence according to TG with binary
variables. DCAN prevalence was 26.54 % and 35.25 % in the two
groups, respectively. A significant differences between the two
groups were reported (P = 0.010)
Fig. 3 Comparison of prevalence of diabetic cardiovascular autonomic
neuropathy (DCAN) according tolow density lipoprotein cholesterol
(LDL). a: Comparison of DCAN prevalence according to LDL with
trinary variables. DCAN prevalence was 28.40 %,28.13 % and 32.86 % in
the three groups, respectively. No significant differences among the
three groups were reported (P =0.622). b: Comparison of DCAN
prevalence according to LDL with binary variables. DCAN prevalence
was 28.31 % and 32.86 % in the two groups, respectively. A significant
differences between the two groups were reported (P = 0.276)
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positively related with the severity of DCAN. Another
key finding was that the severity of lipids profile was in-
dependently and significantly associated with DCAN.
There was a tendency toward an increased lipids profile
risk score with increasing DCAN prevalence. The
MLR model showed that TG, combined with TC and
LDL, was associated with this outcome (P < 0.1 for
LRS-1 and LRS-2).
Diabetic cardiac autonomic neuropathy (DCAN) is a
common complication of DM, which is an independent
risk factor for cardiovascular and overall mortality, pos-
sibly due to increased risk of ventricular arrhythmias
and stroke [17, 18]. In T1DM patients, the reported
prevalence rates vary between 2.4 % and 36 %[19, 20]. In
T2DM patients, the DCAN prevalence is between 30–
60 % [13, 21]. In our study, 29.01 % of the enrolled
T2DM patients had DCAN, which is consistent with the
above published data. However, the previous clinical tri-
als show that DM is not the only risk factor for CAN,
because the intensive glucose control can only decrease
the incidence of new CAN cases by 53 %[19] and CAN
may also occur in newly diagnosed T1DM patients [22].
These results mean that other risk factors are involved
in the pathogenesis of CAN, apart from DM.
Dyslipidemia is one such risk factor. Several large-
scale clinical studies have indicated that a poor lipids
profile is linked with neuropathy development and pro-
gression, independent of glycemic control [23–26], and
it has recently been identified as a major independent
risk factor for the development of neuropathy [27]. In
this study, we found that the level of TG is positively re-
lated to the prevalence of DCAN in diabetes patients,
and can also predict the severity of DCAN when
Table 2 Univariate analysis to include independent variables for
diabetic cardiovascular autonomic neuropathy
Variable β SE P value OR 95 % CI
Lipid profile
TC mmol/L 0.067 0.065 0.308 1.069 0.94–1.215
TG mmol/L 0.257 0.06 <0.001 1.293 1.15–1.455
HDL mmol/L −0.231 0.243 0.340 0.793 0.493–1.277
LDL mmol/L −0.040 0.086 0.645 0.961 0.811–1.138
Covariance
Age years 0.035 0.009 <0.001 1.036 1.018–1.054
Gender male 0.200 0.146 0.172 1.221 0.917–1.627
BMI kg/cm2 0.029 0.012 0.043 1.03 1.01–1.07
SBP mmHg 0.004 0.004 0.242 1.004 0.997–1.011
DBP mmHg 0.002 0.007 0.806 1.002 0.988–1.016
FPG mmol/L 0.098 0.026 <0.001 1.103 1.048–1.161
PBG mmol/L 0.081 0.017 <0.001 1.084 1.049–1.121
FINS uml 0.006 0.003 0.031 1.006 1.001–1.012
SCr μmolL 0.005 0.003 0.073 1.005 1.00–1.011
HR bpm 0.091 0.009 <0.001 1.095 1.076–1.114
Smoking yes 0.210 0.18 0.242 1.234 0.868–1.756
DMD years 0.031 0.012 0.010 1.031 1.007–1.056
HTN yes 0.120 0.153 0.433 1.128 0.835–1.523
HTND years 0.014 0.007 0.050 1.014 1.00–1.028
MetS yes 0.527 0.175 0.003 1.694 1.202–2.387
Note: SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting
plasma glucose, PBG plasma blood glucose, FINS fasting blood insulin, TC
serum total cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol,
LDL low density lipoprotein cholesterol, SCr serum creatinine, HR heart rate, MetS
metabolic syndrome, HTN Hypertension
Table 3 Association analysis between lipid profile for diabetic
cardiovascular autonomic neuropathy using multiple variable
logistic regression analysis
Model Variable β SE P value OR 95 % CI
Model 1
TC 0.273 0.265 0.304 1.313 0.781–2.208
TG 0.223 0.106 0.036 1.25 1.015–1.54
LDL −0.454 0.304 0.136 0.635 0.35–1.154
HDL 0.545 0.380 0.151 1.725 0.819–3.631
Model 2
TC 0.130 0.322 0.686 1.139 0.606–2.139
TG 0.355 0.213 0.096 1.427 0.939–2.167
LDL 0.031 0.337 0.928 1.031 0.533–1.996
HDL 0.358 0.250 0.152 1.430 0.876–2.336
Note: Model 1: lipid profiles with continuous variable, Model 2: lipid profiles
with binary variable
TC serum total cholesterol, TG triglyceride, LDL low density lipoprotein
cholesterol, HDL high-density lipoprotein cholesterol, BMI body mass index; all
models adjusted for age, gender, smoking, BMI, blood pressure, glucose
profile, renal function, medical history
Fig. 4 Comparison of prevalence of diabetic cardiovascular
autonomic neuropathy (DCAN) according tohigh-density lipoprotein
cholesterol (HDL). Comparison of DCAN prevalence according to
HDL. DCAN prevalence was 28.89%n and 29.47 % in the two groups,
respectively. There were no significant differences between the two
groups (P = 0.371)
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individualized to age, education, and medical and ther-
apy history. In other studies, the relationship between
TG and CAN has also been shown. In a Greek popula-
tion, Voulgari et al. found that CAN occurred in patients
with a higher TG level, and that the TG level is posi-
tively related to the prevalence of CAN, no matter
whether the individual has T1DM or T2DM [28]. The
same result was also shown in a population from
Finland, in which parasympathetic function detected by
a deep-breathing test was used to diagnose CAN [29].
However, some other published data did not find the
same connection. Witte et al. found no association be-
tween TG and CAN in T1DM patients, but that HDL
might have a weak negative relationship with CAN [30].
However, in our study, no correlation between HDL and
CAN was found.
Although the relationship between dyslipidemia and
neuropathy has been confirmed in clinical trials, the
underlying mechanisms by which dyslipidemia damages
the neural system are not totally clear. Of these, oxida-
tive stress, as induced by dyslipidemia, is possibly the
most important. In rats, a high-fat diet alone can in-
crease oxidative stress, and they develop sensory and
motor nerve conduction velocity deficits before the oc-
currence of impaired glucose tolerance [27]. Enhanced
oxidative stress can contribute to the pathology of neural
dysfunction in diabetes and has been proposed as a
mechanism that contributes to the pathogenesis of neur-
opathy [31, 32]. A recent study showed the activity of
paraoxonase-1 (PON-1),which can reduce hydroperox-
ides and hydroxyl radicals and is treated as a peroxidase-
like enzyme. It decreased in high-fat diet-fed mice, while
Fig. 5 Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according to lipid profile risk score (LRS). a: Comparison of
DCAN prevalence according to LRS-1. DCAN prevalence was 25.48 %, 32.70 % and 37.84 % in the three groups, respectively. There were significant
differences among the three groups (P for difference = 0.018 and P for a trend =0.005). b: Comparison of DCAN prevalence according to LRS-2. DCAN
prevalence was 26.18 %, 32.08 % and 42.86 % in the four groups, respectively. There were significant differences among the three groups (P for
difference = 0.024 and P for a trend =0.007). c: Comparison of DCAN prevalence according to LRS-3. DCAN prevalence was 27.14 %,30.14 % and
37.50 % in the three groups, respectively. There were no significant differences among the three groups (P for difference = 0.140 and P for a
trend =0.059). d: Comparison of DCAN prevalence according to LRS-4. DCAN prevalence was 28.14 %, 30.32 % and 40.00 % in the three
groups, respectively. There were no significant differences among the four groups (P for difference =0.548 and P for a trend =0.363)
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the activities of MDA, NO levels, SOD, and GPx were
enhanced following the increased oxidative stress when
they were fed with such a diet [33]. Another mechanism
may be related to inflammation TNF-a and TGF-β, two
important pro-inflammatory cytokines, were higher in
high-fat diet mice than in vehicle-treated mice [33], but
whether anti-inflammation chemicals can reduce the
progress of neuropathy in diabetic or/and dyslipidemia
patients is not yet known.
Several potential limitations of this study should be
addressed. First, this is a cross-sectional study exploring
the associations among variables, so that we are unable
to confirm a direct causal relationship. Additionally, it is
important to mention that our study was performed on
Chinese individuals, and there is alack of evidence con-
cerning application to other ethnicities. Finally, our find-
ings may be less applicable to younger or elderly
populations, due to all subjects being aged between 30
and 80 years.
Conclusion
Our findings offer evidence that TG and the severity of
lipids profile are significantly and independently associ-
ated with DCAN, respectively; and that DCAN preva-
lence was frequent in higher lipids profiles risk scores.
These findings indicate that the lipids profile might
influence the development of DCAN, providing insight
into biological functions.
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